Drug intelligence / Profile preview

CP1

Development stage: Preclinical
Lead developer: Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Administration: Oral

Overview

**CP1** is an investigational traditional Chinese medicine formula referred to in Chinese as **CP1号方**. It is being studied by Dongzhimen Hospital, Beijing University of Chinese Medicine, for chronic prostatitis classified as NIH category III with a qi stagnation and blood stasis traditional Chinese medicine pattern. Public trial-registration information identifies CP1 as a therapeutic study intervention, but does not disclose its constituent herbs, dosage form, route of administration, manufacturer, or molecular mechanism.

Other names: CP1号方

Beyond the preview

Go deeper on CP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP1.

Explore the full profile